Home » Newsletters » BioWorld Science

BioWorld Science

Nov. 10, 1999

View Archived Issues

BioTransplant/MGH report extensively on xenotransplantation research at recent congress

Exelixis and Pharmacia & Upjohn expand collaboration

New data reported for Tamiflu as influenza treatment and prophylaxis

HepaVec acquires majority stake in MondoGen

D-Pharm completes toxicity testing of DP-b99 in preparation for phase I trials later this year

Cromafiban stands head and shoulders above others in its class

CombiChem reaches second milestone in collaboration with Teijin

Third quarter activities summarized by MedImmune

BMS reports R&D progress during the third quarter

Anti-H. pylori compound isolated from Acinetobacter at Takeda laboratories

Japanese researchers present new protein-tyrosine-phosphatase inhibitors

Dainippon discloses new compounds useful for the treatment or prophylaxis of liver disease

R&D highlights at Corixa during 3rd quarter

Vasopeptidase inhibitor steals the show at AHA

Kowa's new antiallergic agents inhibit IgE antibody production

Pyridone ACAT inhibitors in development at Sumitomo

Inhibition of telomerase as anticancer strategy under study at Chugai

Studies on absorption of ME-3229 in rat intestinal segments

Inhibitors of cytokine-mediated eosinophil survival as potential agents for asthma

News from AHA: Bayer presents promising new treatment for atherosclerosis

Aronex to lead further development of new liposomal platinum product

Teva licenses European rights to Parkinson's disease drugs to Lundbeck

Preclinical results indicate potential utility of JMR-193 in myocardial perfusion imaging

Specific inhibitors of cancer cell mitogenic pathways tested in combination with radiation

Novel photosensitizer from Miravant prevents postangioplasty restenosis in pig model

Small-molecule inhibitor of receptors of the EGF family may offer superior alternative to Herceptin

Nippon Zoki compound evaluated in diabetic patients with renal failure

Farnesyltransferase inhibitors + radiation synergistic in human tumors expressing mutated ras

Results of phase II trial of GA-EPO presented at ASN

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 4, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 4, 2025.
Epigenetic technology could eliminate misfolded prion proteins
BioWorld Science
The number of deaths caused by prion diseases reaches about 30,000 annually. Only 5 months pass from the diagnosis of seemingly healthy patients to the fatal...
Mesothelin is biomarker, potential target in arthritic bone damage
BioWorld Science
In a recent study published in Cell Reports Medicine, researchers from the Institute of Chinese Materia Medica of the China Academy of Chinese Medical Sciences...
Gene therapies aim for the big goal of edits in vivo
BioWorld Science
The field of gene therapy is experiencing major advances driven by precise editing technologies, such as base and prime editing, and by the design of increasingly...